Enhanced reactivation of UV-irradiated adenovirus 2 is not associated with enhanced mutagenesis in carcinogen-pretreated HeLa cells.
Treatment of HeLa cells with low doses of the carcinogens aflatoxin B1, methyl methanesulfonate (MMS) or ethyl methanesulfonate (EMS) increases the survival rate of UV-irradiated adenovirus 2 (ade2). This increase is maximal if the time interval between cell treatment and virus infection is delayed by 36 h. No enhanced mutagenesis was found measuring the reversion frequency of a temperature-sensitive mutant of ade2 grown in HeLa cells treated with the same carcinogens. The enhanced viral reactivation observed does not, therefore, display a significant error-prone component.
D000260:Adenoviruses, Human / Q000235:genetics* / Q000528:radiation effects; D016604:Aflatoxin B1; D000348:Aflatoxins / Q000494:pharmacology*; D004260:DNA Repair / Q000187:drug effects*; D005020:Ethyl Methanesulfonate / Q000494:pharmacology*; D006367:HeLa Cells; D006801:Humans; D008741:Methyl Methanesulfonate / Q000494:pharmacology*; D009154:Mutation / Q000187:drug effects*; D014466:Ultraviolet Rays; D014779:Virus Replication / Q000187:drug effects / Q000528:radiation effects*
D000348:Aflatoxins; D005020:Ethyl Methanesulfonate; D016604:Aflatoxin B1; D008741:Methyl Methanesulfonate